Jeffrey Hawkins has served as our President and Chief Executive Officer and as a member of our board of directors since October 2022. He previously served as President and Chief Executive Officer of Truvian Sciences, Inc., a biotechnology company focused on blood testing, from January 2018 to July 2022 and as a technical advisor from August 2022 to September 2022. Prior to Truvian Sciences, from October 2015 to January 2018, Mr. Hawkins served as Vice President and General Manager, Reproductive and Genetic Health at Illumina, Inc., a biotechnology company focused on genomics and human health. From December 2009 to October 2015, he held senior leadership positions at GenMark Diagnostics, Inc., a syndromic molecular diagnostics company focused on infectious disease, including most recently as Senior Vice President, Global Marketing and Program Management. Earlier in his career, Mr. Hawkins served in various executive director, executive marketing and business development roles at Hologic, Inc., a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical product; Osmetech Technology, Inc., a molecular diagnostics provider; and Third Wave Technologies Inc., a provider of DNA and RNA analysis products to clinical, research and agricultural customers. He also held positions of increasing responsibility in marketing, product development, and operations at Abbott Laboratories, a medical devices and technologies provider, and Sysmex America, Inc., a medical diagnostic solutions provider.
Mr. Hawkins holds a B.A. in chemistry from Concordia University and an M.B.A. from Keller Graduate School of Management. Mr. Hawkins’ qualifications to serve on our board of directors include his extensive executive leadership experience and his background in the life sciences industry, including in the genetic health industry.
